共 251 条
[1]
Quigley HA(2011)Glaucoma Lancet (Lond) 377 1367-1377
[2]
Klein R(2013)The prevalence of age-related eye diseases and visual impairment in aging: current estimates Invest Ophthalmol Vis Sci 54 Orsf5-orsf13
[3]
Klein BE(2015)Intraocular pressure changes in non-glaucomatous patients receiving Intravitreal anti-vascular endothelial growth factor agents PLoS One 10 e0137833-602
[4]
Kiddee W(2017)Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario Indian J Ophthalmol 65 596-4.e1
[5]
Montriwet M(2008)Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents Am J Ophthalmol 146 930-183
[6]
Jain P(2010)Complications of intravitreal injections Curr Opin Ophthalmol 21 178-1301
[7]
Sheth J(2012)A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab Retina 32 1295-2572
[8]
Anantharaman G(2019)Incidence of glaucoma or ocular hypertension after repeated anti-vascular endothelial growth factor injections for macular degeneration Clin Ophthalmol 13 2563-110
[9]
Gopalakrishnan M(2010)Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections J Ocul Pharmacol Ther 26 105-682
[10]
Kim JE(2018)The real-world effect of Intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure: an analysis using the IRIS registry Ophthalmology. 125 676-314